AdaptHealth Corp. 8-K Summary
Business Context and Reporting Period
On July 19, 2026, AdaptHealth Corp. (AHCO) filed a Form 8-K to report the entry into a Material Definitive Agreement. The Company, incorporated in Delaware, operates in the medical device and services sector. This filing details a strategic divestiture of a specific business segment.
Key Financial Metrics and Transaction Terms
The filing discloses a definitive asset purchase agreement with RGH Enterprises, LLC, a wholly owned subsidiary of Cardinal Health, Inc. Key financial terms include:
- Purchase Price: $235.0 million in cash, subject to customary post-closing net working capital adjustments.
- Escrow Arrangements: At closing, the Purchaser will deposit $8.0 million to secure purchase price adjustments and $18.8 million to secure indemnification obligations.
- Termination Fee: If the agreement is terminated due to failure to obtain antitrust clearance, the Purchaser must pay a fee of $9.4 million.
- Financial Statements: This 8-K filing does not provide standalone revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company or the divested business.
Material Changes and Transaction Scope
The transaction involves the sale of substantially all assets related to AdaptHealth's diabetes treatment business (medical devices and related services). The Purchaser will assume certain specified liabilities. This represents a material change in the Company's asset base and operational scope, effectively exiting the diabetes treatment segment in North America.
Outlook, Risks, and Covenants
Closing Conditions: The transaction is subject to customary conditions, including antitrust clearance (Hart-Scott-Rodino), regulatory approvals, accuracy of representations, no material adverse effect, and the acceptance of employment offers by at least 80% of offered employees plus a specified key employee.
Restrictive Covenants: Post-closing, AdaptHealth is bound by:
- A four-year non-competition covenant in North America regarding the diabetes business.
- A two-year non-solicitation covenant for transferred employees and contractors.
- A seven-year confidentiality covenant regarding non-public business information.
Risks and Contingencies: The transaction may be terminated if closing does not occur within twelve months (subject to extensions), upon uncured breaches, or if a governmental authority permanently prohibits the deal. Indemnification obligations generally survive for 18 months, with longer periods for fundamental representations.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $235.0 million purchase price after working capital adjustments.
- Monitor regulatory filings for antitrust clearance status and any potential delays.
- Confirm the retention rate of key employees and the 80% employment offer acceptance threshold.
- Review the Transition Services Agreement and IP License Agreement (referenced as ancillary agreements) to understand ongoing operational dependencies.
- Assess the impact of the divestiture on AdaptHealth's future revenue streams and strategic focus post-closing.